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A b s t r A c t
Milk thistle has been used for treating liver disorders since approximately 2000 years. 
Silybum marianum and its seeds contain a whole family of natural compounds, called 
flavonolignans. Silimarin is a dry mixture of these compounds, which are extracted 
after processing with ethanol, methanol, and acetone. Silimarin contains mainly sili-
bin A, silibin B, taxifolin, isosilibin A, isosilibin B, silichristin A and silidianin. Milk 
thistle has been suggested to inhibit cell proliferation and to induce apoptosis, while 
also having anti-angiogenic properties. Its mechanisms of action involve inhibition of 
tumor angiogenesis biomarkers (CD31 and nestin) and molecules regulating angio-
genesis (VEGF, VEGFR1, VEGFR2, phospho-Akt and HIF-1a), while other path-
ways such as the Wnt/β-catenin pathway, cyclin-dependent kinases and MAPK have 
also been implicated in its actions. Ongoing research has focused on the improvement 
of milk thistle’s bioavailability and its probable use as an adjuvant in standardized 
chemotherapy in the near future.
I n t r o d u c t I o n
The Greek philosopher, physician and botanologist Theophrastus was the first to 
describe milk thistle, under the name “Pternix”, for its healing properties in the 4th 
century B.C. Milk thistle has been used for treating liver disorders since approximately 
2000 years (Fig. 1).1 Pliny the Elder (23-79 A.D.) suggested that a mixture of honey 
and the plant’s juice could serve to “carry off the bile”.2 Silybum marianum and its 
seeds contain a whole family of natural compounds, called flavonolignans. Silimarin is 
a dry mixture of these compounds, which are extracted after processing with ethanol, 
methanol, and acetone. Silimarin contains mainly silibin A, silibin B, taxifolin, isosilibin 
A, isosilibin B, silichristin A and silidianin. In 1959, the first member of this family was 
discovered, silibin, which is the most extensively researched one. Silibin is a mixture 
of silibin A and silibin B in approximately 1:1 ratio. 3-7 
A n t I c A n c e r  A c t I v I t y  o f  s I l I m A r I n ,  
I n  v I t r o  s t u d I e s
Silimarin’s non-toxicity for normal tissues, its lack of adverse side-effects even 
in high doses, and its being inexpensive and easily available have made silimarin an 
attractive candidate for combined use with doxorubicin in order to decrease adverse 
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side effects and increase treatment results of doxorubicin.8-11 It 
has recently been documented that silimarin has a synergistic 
effect on apoptosis induced by doxorubicin in human breast 
carcinoma cell line (MCF-7), thus allowing for a dose reduc-
tion of doxorubicin and minimizing doxorubicin’s adverse side 
effects.12 In addition, silibin alone has been demonstrated to 
induce apoptotic cell death in MCF-7 cells. Furthermore, the 
combination of silibin and UVB resulted in an additive effect 
on apoptosis in MCF-7 cells. These in vitro results are sug-
gestive of the role of silibin as a supplemental agent for the 
treatment of patients with breast cancer.13 Also, the effect of 
silibin on human colon cancer HT-29 cells has been studied 
and the results have indicated a loss of cell viability that was 
time dependent.14 Reduction in serum prostate-specific antigen 
(PSA) levels has been proposed as an endpoint biomarker 
for hormone-refractory human prostate cancer intervention. 
Researchers have tested if silibin decreased PSA levels in 
hormone-refractory human prostate carcinoma LNCaP cells. 
Silibinin treatment of cells grown in serum resulted in a signifi-
cant decrease in PSA together with an almost complete inhibi-
tion of cell growth by means of G1 arrest in cell cycle. Silibin-
induced G1 arrest was accompanied by a significant decrease 
in the kinase activity of cyclin-dependent kinases (CDKs) and 
associated cyclins.15 The role of neo-angiogenesis in prostate 
cancer growth and metastasis has been well established, but 
the development of effective and non-toxic pharmacological 
inhibitors of angiogenesis still remains an unaccomplished 
goal. Immunohistochemical analyses have confirmed inhibition 
of tumor angiogenesis biomarkers (CD31 and nestin) and mol-
ecules regulating angiogenesis (VEGF, VEGFR1, VEGFR2, 
phospho-Akt and HIF-1a).16 It is widely known that the canoni-
cal Wnt/β-catenin signaling pathway has a crucial role in cell 
proliferation, migration, and differentiation.17 Data from the 
above-mentioned study have implicated silibin as a novel small 
molecule Wnt/β-catenin signaling inhibitor by suppressing Wnt 
co-receptor LRP6 expression at the transcription level, and 
that the anti-cancer activity of silibin has been related to this 
inhibitory potential on Wnt/LRP6 pathway.18 Treatment with 
active compounds of silimarin, isosilibin B and isosilibin A, 
has been demonstrated to result in growth inhibition and cell 
death together with a strong G1 arrest and apoptotic death in 
human prostate carcinoma LNCaP and 22Rv1 cells.19 In vitro 
studies have also shown that silibin inhibits constitutively active 
Stat3 and induces apoptosis in DU145 cells, while other studies 
have documented that silibin synergizes human prostate carci-
noma DU145 cells with doxorubicin, cisplatin and carboplatin 
induced growth inhibition and apoptotic death.20 Synergistic 
effects of silibin with doxorubicin and cisplatin have also been 
reported in breast and ovarian cancer cell lines.21,22 To sum 
up, anti-cancer activity of silimarin has been demonstrated in 
human breast cancer, skin cancer, androgen-dependent and 
independent prostate cancer, cervical cancer, colon cancer, 
ovarian cancer, hepatocellular carcinoma, bladder cancer and 
lung cancer cells.20-24
A n t I c A n c e r  A c t I v I t y  
o f  s I l I m A r I n ,  I n  v I v o  s t u d I e s
The efficacy of silimarin has been demonstrated using 
various transgenic models. Further studies suggested the 
important role of silimarin in inhibiting the chemical- and 
UV-induced skin carcinogenesis.24 Recently, Gu et al have 
demonstrated that topical or dietary silibin treatment causes a 
strong protection against UVB-induced photo-carcinogenesis 
fIgure 1. Milk thistle in the Municipality of Marathonas, Ath-
ens, Greece.
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by inhibiting cell proliferation, inflammation and angiogen-
esis in SKH-1 hairless mice.25 It has also been suggested that 
dietary feeding of silibin prevents UVB radiation-induced 
skin damages including thymidine dimer-positive cells, 
proliferating cell nuclear antigen expression and apoptotic 
sunburn cells. Studies have documented silibin to inhibit the 
member of MAPKs family (ERK1/2, JNK and p38) and Akt 
activation induced by either acute or chronic UVB exposure 
of SKH-1 mouse skin.26,27 Regarding prostate cancer, dietary 
administration of silimarin has decreased the incidence of 
3,2-dimethyl-4-aminobiphenyl (DMBA)-induced prostatic ad-
enocarcinoma in male F344 rats.28 Studies have shown that di-
etary administration of silibin has resulted in inhibition of the 
advanced human prostate tumor xenograft growth in athymic 
nude mice by exhibiting anti-proliferative, pro-apoptotic and 
anti-angiogenic properties against prostate cancer.23,24 Re-
cently, dietary silibin has been shown to inhibit prostate tumor 
growth and progression in transgenic adenocarcinoma of the 
mouse prostate (TRAMP) mice by modulating the expression 
of CDKs, CDKIs, insulin like growth factor (IGF)-1 and IGF 
binding protein-3.29 Vinh et al have shown that administra-
tion of silimarin reduces the labeling index for BrdU and 
the cyclin D1-positive cell ratio in various bladder lesions.30 
Chemo-preventive efficacy of silibin against lung cancer has 
been suggested by a study that has found that silibin suppresses 
the growth of human non-small-cell lung carcinoma A549 
xenograft growth in athymic BALB/c nu/nu mice.31 Silibin 
also reduces systemic toxicity of doxorubicin with an enhanced 
therapeutic efficacy by modulating NF kappa B mediated 
signaling pathway in this model.32,33 Anti-cancer properties 
of silimarin have also been documented in in vivo models of 
colon cancer. Silibin administered via feeding exhibited potent 
pro-apoptotic and multi-targeted effects at the molecular level. 
The effective reduction of pre-neoplastic lesions by silibin 
supports its use as a natural agent for colon cancer chemo-
prevention.34 Different laboratories have also investigated 
the potential of silimarin against breast cancer and there are 
conflicting reports regarding the chemo-preventive efficacy of 
silimarin/silibin in mammary carcinogenesis.23,35 Dietary sup-
plementation of silimarin increased the number of mammary 
tumors in 1-methyl-1- nitrosourea (MNU)-induced mammary 
carcinogenesis and also increased incidence of mammary 
tumors in MMTVneu/HER2 transgenic mice.36 On the other 
hand, silibin treatment was found to inhibit development of 
mammary tumors as well as lung metastasis in HER-2/neu 
transgenic mice.37 Anti-cancer effects of silimarin have also 
been documented from xenograft models of ovarian cancer. 
Gallo et al have found that oral administration of Silipide to 
nude mice bearing tumor xenograft of human ovarian cancer 
cell line A2780 produces significant tumor inhibition. The 
down-regulation of VEGF receptor 3 and up-regulation of 
angiopoietin-2 were the plausible mechanisms for this anti-
angiogenic activity.38 Giacomelli et al have shown that Silipide 
administration increased the anti-tumor activity of cysplatin 
in mice, while reducing the toxicity associated with this anti-
cancer drug.39 Anti-cancer effects of silibin have been reported 
in renal cell carcinoma, where oral administration of silibin 
was found to suppress the growth of local and metastatic tu-
mors in xenograft model of renal cell carcinoma. Overall, the 
above-mentioned studies provide a rationale for silimarin’s 
utility in future clinical trials.
s I l I m A r I n  I n  c l I n I c A l  t r I A l s
The efficacy of silimarin is currently being evaluated in 
cancer patients alone or in combination with other chemo-
therapeutic agents. Several doses of silimarin have been tested. 
Silipide, a silibin formulation, was given orally to patients with 
colorectal adenocarcinoma at doses of 360, 720, or 1440 mg 
daily for 7 days and high levels of silibin were achieved in the 
colorectal mucosa of the patients.40 Researchers have also re-
cently completed a phase-I clinical trial with silibin in prostate 
cancer patients. Silibin phytosome (SiliphosR), a commercial 
preparation of silibin, at a dose of 13 g, divided in 3 daily doses, 
appears to be well tolerated in patients with advanced prostate 
cancer.41 Now, they are starting a pilot Phase II clinical trial 
to estimate the effects of silibin administration on prostate 
cancer progression using surrogate biomarkers as endpoints. 
Silimarin has been used (along with soy, lycopene and anti-
oxidants) in a phase III clinical trial to delay prostate specific 
antigen progression after prostatectomy and radiotherapy in 
prostate cancer patients.42 Chemotherapeutic agents provide 
significant protective effects against many cancers; however, it 
has been shown that hepatotoxicity is a frequent adverse side 
effect caused by these drugs. Studies have shown that milk 
thistle has been used in treatment of chemotherapy induced 
hepatotoxicity and has been found to protect the liver during 
chemotherapy. Invernizzi et al have shown similar results with 
the use of silimarin in a 34-year-old woman with promyelocytic 
leukemia. The investigators administered 800 mg/d silimarin 
during the patient’s methotrexate and 6-mercaptopurine 
chemotherapy. During the 4 months of treatment with silima-
rin, the patient had normal liver transaminase levels and there 
was no further interruption in her therapeutic process. Milk 
thistle supplementation in children with acute lymphopblastic 
leukemia (ALL) and higher hepatic toxicity has been related 
to decreases in serum transaminases and a greater than 50% 
reduction in total bilirubin.43 Studies have demonstrated that 
silimarin may play a role in adjuvant cancer therapy. In vitro 
studies have shown that silimarin increased daunomycin ac-
cumulation, potentiated doxorubicin toxicity and inhibited 
efflux of these drugs from cancer cells. In a nonrandomized 
study, patients with brain metastases receiving stereotactic 
radiotherapy with omega 3 fatty acids and silimarin had longer 
survival times and a decreased number of radio-necroses.44
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s I l I b I n ’ s  b I o A v A I l A b I l I t y
Silibin is rapidly absorbed from the stomach, but absorp-
tion is low due to low water solubility. The use of labeled silibin 
in the rat has enabled to show that the intestinal absorption of 
20 mg/kg amounts to approximately 35%. Peak radioactivity 
is found in the plasma 30 minutes after ingestion.45 Bioavail-
ability is also low due to high reactivity with phase II conjuga-
tion in the liver. Approximately 90% of the circulating silibin 
is conjugated with sulfates and glucuronides. Because of the 
potential inactivation of CYP3A4 and CYP2C9, silibin should 
be carefully co-administered with drugs (e.g. nifedipine, metro-
nidazole, irinotecan, indinavir), and should be cleared by drugs, 
especially in high doses. Elimination of conjugated and uncon-
jugated forms is equally fast with a mean elimination half-life 
of 6.32 hours. Also, silibin’s excretion in the urine ranges from 
1 to 7%.46 Bioavailability of silibin can be enhanced up to three-
fold eight hours after consumption of a phytosome form, i.e. a 
complex of a natural active ingredient and a phospholipid, in 
healthy individuals.47 Parenteral administration of silibin seems 
to be better, while using a phosphatidyl choline-bile salt-mixed 
micelles formulation. Silibin B and silichristin demonstrate 
nonlinear pharmacokinetics compared to the rest of silimarin’s 
compounds. This is attributed to the saturation of conjugating 
enzymes and delayed elimination as a result of the extensive 
entero-hepatic cycling of the aforementioned conjugates of 
the silibin compounds. Peak concentrations were achieved 
for all doses after 2 hours and silimarin compounds’ half-life 
ranged from 0.8 to 2.4 hours. The highest bioavailability was 
documented for silibin A at the 700-mg dose.48 Comparison 
of 3 silibin-containing preparations (liverman capsule, legalon 
capsule, and silimarin tablet) revealed best absorption and 
bioavailability for the liverman capsule.49
Silibin is known to have poor bioavailability for two main 
reasons, its multi-ring structure that is too large to be absorbed 
by simple diffusion and its poor miscibility with oils and other 
lipids, severely limiting its ability to cross the lipid-rich outer 
membrane of the enterocytes of the small intestine.50 Compara-
tive analyses of two clinical studies revealed high bioavailability 
of silibin in the colon tissue but poor levels into prostate tissue 
suggesting the organs specific differences in the silibin bioavail-
ability following oral administration.51 Recently, the bioavail-
ability of silibin was reported to be significantly enhanced when 
administered in beagle dogs as silibin-nanosuspensions.52 This 
study also suggests that uptake and bioavailability of silibin 
could be further enhanced through altering the nanoparticle 
size.52 To sum up, recent efforts towards increasing the bio-
availability of silibin are really encouraging.
Despite the overall safety of milk thistle seen in these 
few human studies, there are still no clear data to suggest 
anti-cancer activity among patients with cancer. Longer-term 
toxicology studies of milk thistle have not shown evidence of 
cancer promotion and side-effects for milk-thistle components 
in human beings are usually mild (diarrhea, gastrointestinal 
upset, and transiently raised concentrations of liver enzymes).7 
c o n c l u s I o n
Milk thistle has been suggested to inhibit cell prolifera-
tion and to induce apoptosis, while having anti-angiogenic 
properties, too. Its mechanisms of action involve inhibition of 
tumor angiogenesis biomarkers (CD31 and nestin) and mol-
ecules regulating angiogenesis (VEGF, VEGFR1, VEGFR2, 
phospho-Akt and HIF-1a), while other pathways such as the 
Wnt/β-catenin pathway, cyclin-dependent kinases and MAPK 
have also been implicated in its actions. In this view, the bio-
availability of its major constitute silibin has to be improved in 
the near future, using forms such as nano-formulations for ex-
ample. Nevertheless, several limitations should be mentioned 
and emphasized, including the lack of an official recommen-
dation for its use, apparently due to lack of evidence-based 
information on clinical applications. Thus, on the basis of the 
existing data, milk thistle remains in the category of dietary 
supplements. Thus, the absence of adequate evidence for its 
recommendation as a treatment for cancer holds true for the 
time being. Further studies are warranted to further confirm 
or not milk thistle as a useful tool to decrease the adverse side 
effects of standardized chemotherapeutics.
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